This week we discussed the ASCEND trial published in Annals of Internal Medicine, on the comparative effectiveness of cognitive behavioural therapy and Sertraline in patients on dialysis with depression.
The article is available here.The NephJC summary can be read here, with links to the visual abstract.Links from the show:In the background section, we mentioned the data from a recent JASN study on cardiovascular safety of different antidepressants. The contrast with the CAST trial came up as well. PDF links to the BDI, QIDS-SR and QIDS-C scores.
KIDNEYCon 2020 will be in April. Follow @KIDNEYCon to stay updated, as well for the links to the recorded sessions from #KIDNEYCon 2019.Host: Joel TopfDiscussants: Swapnil Hiremath, Jennie Lin and Matt Sparks. We missed Samira Farouk who was travelling.

Freely Filtered 002 ASCEND

Twice monthly (aspirational) recap of the NephJC journal club. NephJC reviews the most important manuscripts which are driving nephrology forward and improving our understanding of the kidney.

Medicine

Science & Medicine

Science

Health & Fitness

On May 24th, at the ERA meeting in Stockholm Sweden (this will not be the last GLP1ra talk at Stockholm), Vlado Perkovic presented the previously spoiled results of FLOW. In addition to simultaneous publication in the NEJM, it made the front page in newspapers around the world. As one headline writer said, “Is there anything Ozempic can’t do?”

Episode 71: The Spice must FLOW!

Nothing terrifies nephrologists, quite like the consult from labor and delivery. And one of the most vexing questions is, “Is this preeclampsia or proteinuric CKD or a lupus flare?” Perhaps a newly approved blood test will be able to shed light on this clinical conundrum. The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) has appeared predictive of severe preeclampsia. The PRAECIS trial evaluated this is a prospective manner.

Join the filtrate as we do a truly incompetent job discussing this study.

Episode 70: Predicting Preeclampsia, the PRAECIS trial

FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?

Episode 69:DUPLEX Sparsentan, it’s no Acthar Gel

Beep Beep. Hey intern the patient’s blood pressure is 160/95. Do you want to do something.

No. The answer is no.

But honestly we have all been guilted into ordering some clonidine or god forbid some IV hydralazine.

Stop it. Just stop it.

Join the filtrate as we dissect a recent study looking at this issue with the lead author.

Freely Filtered 68: Inpatient hypertension

NephMadness prides itself on not repeating topics. Most topics don’t get revisited for years after a single appearance. But one region stands alone. One region is making its fourth appearance in the 12 year history of NephMadness! That region is Animal House!

Modern medical education doesn’t go to the comparative physiology well very often. So when we do, it is always fresh and exciting. Join the Filtrate as we explore the fascinating world of the Gila Monster and Mourning Dove.

Freely Filtered 002 ASCEND

Download our free app to listen on your phone